Upstream Bio, Inc. (UPB) Stock Forecast & Price Target

Compare

157 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

UPB Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Upstream

Bio, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

UPB Stock 12 Month Forecast

Average Price Target

$52.67

▲(95.29% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Upstream Bio, Inc. in the last 3 months. The average price target is $52.67 with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 95.29% change from the last price of $26.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,32.52,36.06,39.6,43.14,46.68,50.22,53.76,57.3,60.839999999999996,64.38,67.92,71.46,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,30.802307692307693,32.62461538461538,34.44692307692308,36.269230769230774,38.09153846153846,39.91384615384615,41.73615384615385,43.55846153846154,45.38076923076923,47.20307692307692,49.02538461538462,50.84769230769231,{"y":52.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,29.82769230769231,30.675384615384615,31.523076923076925,32.370769230769234,33.21846153846154,34.066153846153846,34.91384615384615,35.761538461538464,36.60923076923077,37.456923076923076,38.30461538461539,39.152307692307694,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$52.67

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$75

Buy

178.09%

Upside

Reiterated

12/09/25

Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)

Kate Dellorusso

LifeSci Capital

$43

Buy

59.44%

Upside

Initiated

12/02/25

Upstream Bio initiated with an Outperform at LifeSci CapitalUpstream Bio initiated with an Outperform at LifeSci Capital

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

11/25/25

Promising Outlook for Upstream Bio, Inc. Driven by Verekitug's Clinical Advancements

Cory Kasimov

Evercore ISI

$40

Buy

48.31%

Upside

Initiated

11/18/25

Upstream Bio, Inc.'s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Crispr Therapeutics AG (NASDAQ: CRSP) and Upstream Bio, Inc. (NASDAQ: UPB)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/05/25

Promising Outlook for Upstream Bio, Inc. Driven by Strong Drug Developments and Financial Health3:04 PM Upstream Bio (NASDAQ: UPB) Buy (1) ESG Target: NA Q3 – Report THE TD COWEN INSIGHT Verekitug progressing nicely across all studies. Positive Ph2 CRSwNP data provides confidence in upcoming Ph2 asthma data in Q1:26. The bar is ~50-55% AAER reductions vs placebo; we see the stock up +50-100% if this is hit with Q12W dosing and +150-200% with Q24W dosing. The Ph2 COPD trial is enrolling and has great upside potential. $394M cash runway through 2027. Strong Execution On Verekitug Across Indications – Bio reported ($39M) below our ($44M) estimate, including R&D of ($33M) below our ($37M), and SG&A of ($6M) below our ($7M).

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/05/25

Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline1:36 PM Research | Healthcare Upstream Bio, Inc. (UPB) $25.04 Market Value (M): $1,350 Biotechnology Matt Phipps, Ph.D.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$75

Buy

178.09%

Upside

Reiterated

12/09/25

Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)

Kate Dellorusso

LifeSci Capital

$43

Buy

59.44%

Upside

Initiated

12/02/25

Upstream Bio initiated with an Outperform at LifeSci CapitalUpstream Bio initiated with an Outperform at LifeSci Capital

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

11/25/25

Promising Outlook for Upstream Bio, Inc. Driven by Verekitug's Clinical Advancements

Cory Kasimov

Evercore ISI

$40

Buy

48.31%

Upside

Initiated

11/18/25

Upstream Bio, Inc.'s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Crispr Therapeutics AG (NASDAQ: CRSP) and Upstream Bio, Inc. (NASDAQ: UPB)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/05/25

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/05/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Upstream Bio, Inc.

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+11.48%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +11.48% per trade.

3 Months

xxx

Success Rate

8/9 ratings generated profit

Average Return

+36.87%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +36.87% per trade.

1 Year

Matt PhippsWilliam Blair

Success Rate

8/9 ratings generated profit

Average Return

+107.96%

reiterated a buy rating last month

Copying Matt Phipps's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +107.96% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+125.21%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +125.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UPB Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, UPB has received 10 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. UPB average Analyst price target in the past 3 months is 52.67.

Each month's total comprises the sum of three months' worth of ratings.

UPB Financial Forecast

UPB Earnings Forecast

Next quarter’s earnings estimate for UPB is -$0.71 with a range of -$0.90 to -$0.55. The previous quarter’s EPS was -$0.63. UPB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year UPB has Performed in-line its overall industry.

UPB Sales Forecast

Next quarter’s sales forecast for UPB is $527.00K with a range of $0.00 to $751.00K. The previous quarter’s sales results were $683.00K. UPB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year UPB has Performed in-line its overall industry.

UPB Stock Forecast FAQ

What is UPB’s average 12-month price target, according to analysts?

Based on analyst ratings, Upstream Bio, Inc.’s 12-month average price target is 52.67.

What is UPB’s upside potential, based on the analysts’ average price target?

Upstream Bio, Inc. has 95.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is UPB a Buy, Sell or Hold?

Upstream Bio, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Upstream Bio, Inc.’s price target?

The average price target for Upstream Bio, Inc. is 52.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $40.00. The average price target represents 95.29% Increase from the current price of $26.97.

What do analysts say about Upstream Bio, Inc.?

Upstream Bio, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of UPB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Upstream Bio, Inc. (UPB) Stock Forecast & Price Target

UPB Analyst Ratings

UPB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Upstream Bio, Inc.

UPB Analyst Recommendation Trends

UPB Financial Forecast

UPB Earnings Forecast

UPB Sales Forecast

UPB Stock Forecast FAQ

Detailed List of Analyst Forecasts